WebMay 12, 2024 · SAN FRANCISCO, May 12, 2024--Unlearn®, developer of the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies, today announced that the European Medicines Agency (EMA) recently released a draft qualification opinion providing a regulatory framework for the application … WebMay 12, 2024 · Unlearn.AI is the only company creating TwinRCTs™, which combine AI, digital twins, and novel statistical methods to enable smaller, more efficient clinical trials. Unlearn’s technology has been published in conference abstracts and scientific journals, including Scientific Reports - Nature and The International Journal of Biostatistics.
Unlearn Receives Draft Qualification Opinion from European
WebMar 31, 2024 · In the meantime, we continued to develop and test TwinRCTs within new therapeutic areas, entered a multi-year collaboration with Merck KGaA, and doubled the size of our company. WebAI-powered TwinRCTs reach full enrollment faster because they use smaller control groups than other trial designs. 21%. Reduction in control arms during Phase 3 trials in … simplee slayyed hair \\u0026 more aiken sc
EMA qualifies Unlearn’s AI-driven approach for smaller trials
WebMay 12, 2024 · Unlearn.AI is the only company creating TwinRCTs™, which combine AI, digital twins, and novel statistical methods to enable smaller, more efficient clinical trials. … WebThe European Medicines Agency qualifies Unlearn’s PROCOVA™ procedure, which provides the regulatory framework for the application of TwinRCTs to Phase 2 and 3 clinical trials. … WebApr 19, 2024 · Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials Unlearn®, developer of the first machine-learning technology that creates digital twins of patients in clinical trials to enable smaller, faster studies, today announced that it has closed a $50 million Series B funding … simple equation word problems